Endogenous Probes for Drug Transporters: Balancing Vision With Reality

A D Rodrigues1, K S Taskar2, H Kusuhara3

  • 1Pharmacokinetics, Dynamics & Metabolism, Medicine Design, Pfizer Inc., Groton, Connecticut, USA.

Insights

Endogenous probes aid hepatic and renal drug transporter studies in early trials. Further characterization and validation are needed to expand their use in drug-drug interaction assessments.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Clinical Pharmacology

Background:

  • Endogenous probes are identified for hepatic and renal drug transporters.
  • Clinical data suggest their utility in Phase I trials for phenotyping and drug-drug interaction (DDI) assessment.

Purpose of the Study:

  • To highlight the need for expanding the repertoire of endogenous probes.
  • To emphasize the necessity of further characterization and validation of existing probes.
  • To underscore the importance of building compound files for modeling.

Main Methods:

  • Literature review of endogenous probes for drug transporters.
  • Analysis of clinical data regarding probe application in Phase I trials.
  • Identification of gaps in current probe characterization and validation.

Main Results:

  • Existing endogenous probes show potential for subject phenotyping and DDI assessment.
  • There is a recognized need to expand the available menu of probes.
  • Further characterization and validation of current probes are required.

Conclusions:

  • Expanding and validating endogenous probes is crucial for advancing drug transporter research.
  • Enhanced probe utility will improve drug development through better phenotyping and DDI prediction.
  • Development of comprehensive compound files is essential for robust modeling exercises.

Related Concept Videos

Methods for Studying Drug Absorption: In situ01:09

Methods for Studying Drug Absorption: In situ

In situ experiments, such as the Doluisio method and Single-Pass Perfusion technique, provide critical insights into drug uptake by simulating in vivo conditions for drug absorption.
The Doluisio method involves perfusing a prepared segment of a rat's small intestine with a solution of radiolabeled drug and a non-absorbable marker. This helps to differentiate between absorbed and non-absorbed drug concentrations. The intestinal segment is connected at both ends using tubing and syringes,...
753
Nonlinear Pharmacokinetics: Role of Transporters01:27

Nonlinear Pharmacokinetics: Role of Transporters

A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
344
Cellular Membranes and Drug Transport01:24

Cellular Membranes and Drug Transport

Drugs must traverse multiple biological barriers, such as multi-layered skin, single-layered intestinal epithelium, and the plasma membrane, to reach their target sites within the body. The plasma membrane, a highly structured composite of phospholipids, carbohydrates, and proteins, is the cell's protective boundary, facilitating selective substance exchange.
Phospholipids arrange themselves into a bilayer, with hydrophilic heads oriented outward and hydrophobic tails facing inward.
1.8K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
356